IRD
Opus GeneticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful clinical/data milestones or a strategic partnership/licensing deal could materially re-rate the stock, validating platform potential and improving near-term financing prospects.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -21.2.
What can break
Clinical trial failure or negative data readout
Momentum
52
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.82 · Bull $2.91 · Bear $0.91
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-09-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.82
Why
Momentum52 · Δ7d -21.2
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
52
34% active weight
Current posture
7d trendSoftening
Δ7d
-21.2
Δ21d
-41.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 52.4 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$335.35M
Beta
0.58
Shares Out
68.96M
P/E (TTM) · Derived
-4.4
P/S (TTM)
10.04
P/FCF (TTM) · Derived
-7.34
Rev YoY
-20.4%
EPS YoY
+14.2%
Gross Margin
-
Op Margin
-445.4%
Net Debt
-$30.32M
Current Ratio
1.23
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology